Supreme Court unanimously backs Hikma's skinny label fish oil generic

The U.S. Supreme Court issued a unanimous decision favoring Hikma Pharmaceuticals in a dispute over its skinny label version of a prescription-strength fish oil product.

The court ruled that Hikma could market the generic without infringing the patent held by Amarin, which had been the basis of the litigation.

The decision is seen as a win for the generics sector, which has been watching the case closely for its implications on how skinny label strategies can be used to navigate patent protections.

Industry observers note that the ruling may influence future patent challenges and could affect the timing of generic launches for other branded drugs.